Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
Receive an email update when we add a new WEIGHT LOSS article.
The Latest on: Methotrexate and cyclophosphamide
via Google News
The Latest on: Methotrexate and cyclophosphamide
- HIV-related Lymphomaon April 1, 2020 at 5:00 pm
BEMOP: Bleomycin, etoposide, vincristine, methotrexate and prednisolone; CA: Cyclophosphamide and doxorubicin; CDE: Cyclophosphamide, doxorubicin and etoposide; CHOP ...
- B-Cell Agent Shows Promise in Lupus Nephritison April 1, 2020 at 7:41 am
Additional options include rituximab (Rituxan), which typically has been given along with cyclophosphamide, and calcineurin inhibitors given in combination ... one study that included almost 500 ...
- UK coronavirus symptoms list is TOO short – and misses mild signs, warn docson March 27, 2020 at 9:01 am
It is a treatment that lowers your defenses against infection. Here are some examples: corticosteroids, methotrexate, ciclosporin, tacrolimus, azathioprine, cyclophosphamide (non-exhaustive list). 21.
- Which maintenance therapy for ANCA vasculitis?on March 21, 2020 at 9:32 pm
the French Vasculitis Study Group compared the use of methotrexate and azathioprine for maintenance therapy of ANCA-associated vasculitis after induction of remission with cyclophosphamide and ...
- What does treatment of vasculitis consist of?on March 20, 2020 at 5:00 pm
Other medications may include methotrexate or cyclophosphamide (Cytoxin) and a biologic drug called tocilizumab (Actemra). You'll get tocilizumab as an injection under the skin to lower the dose ...
- Connections Between Autoimmune Diseases and Canceron March 6, 2020 at 7:07 am
Cyclophosphamide is an immunosuppressant ... For instance, a drug called methotrexate (used for certain cancers and autoimmune diseases) and a class of drugs called tumor necrosis factor ...
- B-Cell Acute Lymphoblastic Leukemia: Adding Inotuzumab Ozogamicin to Chemotherapyon February 28, 2020 at 9:45 am
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers ...
- ICCG FEC Trialon April 14, 2018 at 7:18 am
A randomised trial comparing cyclophosphamide, methotrexate & 5-fluorouracil (CMF) with 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in patients with node negative primary breast cancer. A ...
- Lupus and the shingles vaccineon March 16, 2017 at 11:37 am
These may include high doses of steroids, mycophenolate mofetil, cyclophosphamide, and any biologic or infusion ... These include low dose prednisone, antimalarials, methotrexate, and azathioprine.
via Bing News